Jaime Ruiz-Tovar1,2, Miguel Angel Carbajo3, Jose Maria Jimenez3, Maria Jose Castro3, Gilberto Gonzalez3, Javier Ortiz-de-Solorzano3, Lorea Zubiaga3,4. 1. Bariatric Surgery Unit, Centro de Excelencia para el Estudio y Tratamiento de la Obesidad, Valladolid, Spain. jruiztovar@gmail.com. 2. Bariatric Surgery Unit, General University Hospital Elche, Alicante, Spain. jruiztovar@gmail.com. 3. Bariatric Surgery Unit, Centro de Excelencia para el Estudio y Tratamiento de la Obesidad, Valladolid, Spain. 4. Bariatric Surgery Unit, General University Hospital Elche, Alicante, Spain.
Abstract
BACKGROUND: One-Anastomosis Gastric Bypass (OAGB) has exponentially increased in the last decade, as it is associated with very low complications, mortality, readmissions and reoperations rates, and shows excellent short- and long-term benefits of weight loss and resolution of comorbidities. The aim of this study was to compare the effect of SG, RYGB, and OAGB, on short- and long-term weight loss and comorbidities resolution. METHODS: A prospective randomized clinical study of all morbidly obese patients undergoing SG, RYGB, and OAGB, as primary bariatric procedures, was performed. Patients were randomly assigned into 3 groups: those patients undergoing SG, those ones undergoing RYGB and those ones undergoing OAGB. BMI, excess BMI loss (EBMIL) and remission of type 2 diabetes (T2DM), hypertension (HT), and dyslipidemia (DL) were assessed. RESULTS:600 patients were included in the study, 200 in each group. Follow-up rate at 5 years postoperatively was 91% in SG group, 92% in RYGB, and 90% in OAGB. OAGB achieves significantly greater EBMIL than RYGB and SG at 1, 2, and 5 years (p < 0.001, respectively). At 5 years, OAGB achieves significantly greater remission of T2DM (p = 0.027), HT (p = 0.006), and DL (p < 0.001) than RYGB and SG. RYGB did not show significant superiority than SG in short- and long-term remission of T2DM and HT, but achieves greater remission of DL (p < 0.001). CONCLUSION:OAGB achieves superior mid- and long-term weight loss than RYGB and SG. There are no significant differences in weight loss between SG and RYGB at 1, 2, and 5 years. OAGB achieves better short- and long-term resolution rates of DM, HT, and DL than SG and RYGB. RYGB and SG obtain similar T2DM and HT remissions, but RYGB reaches significantly greater rates of DL remission. ClinicalTrials.gov Identifier: NCT03467646.
RCT Entities:
BACKGROUND: One-Anastomosis Gastric Bypass (OAGB) has exponentially increased in the last decade, as it is associated with very low complications, mortality, readmissions and reoperations rates, and shows excellent short- and long-term benefits of weight loss and resolution of comorbidities. The aim of this study was to compare the effect of SG, RYGB, and OAGB, on short- and long-term weight loss and comorbidities resolution. METHODS: A prospective randomized clinical study of all morbidly obesepatients undergoing SG, RYGB, and OAGB, as primary bariatric procedures, was performed. Patients were randomly assigned into 3 groups: those patients undergoing SG, those ones undergoing RYGB and those ones undergoing OAGB. BMI, excess BMI loss (EBMIL) and remission of type 2 diabetes (T2DM), hypertension (HT), and dyslipidemia (DL) were assessed. RESULTS: 600 patients were included in the study, 200 in each group. Follow-up rate at 5 years postoperatively was 91% in SG group, 92% in RYGB, and 90% in OAGB. OAGB achieves significantly greater EBMIL than RYGB and SG at 1, 2, and 5 years (p < 0.001, respectively). At 5 years, OAGB achieves significantly greater remission of T2DM (p = 0.027), HT (p = 0.006), and DL (p < 0.001) than RYGB and SG. RYGB did not show significant superiority than SG in short- and long-term remission of T2DM and HT, but achieves greater remission of DL (p < 0.001). CONCLUSION: OAGB achieves superior mid- and long-term weight loss than RYGB and SG. There are no significant differences in weight loss between SG and RYGB at 1, 2, and 5 years. OAGB achieves better short- and long-term resolution rates of DM, HT, and DL than SG and RYGB. RYGB and SG obtain similar T2DM and HT remissions, but RYGB reaches significantly greater rates of DL remission. ClinicalTrials.gov Identifier: NCT03467646.
Authors: Jaime Ruiz-Tovar; Rosana Martínez; José María Bonete; José María Rico; Lorea Zubiaga; Maria Diez; Carolina Llavero Journal: Obes Surg Date: 2016-01 Impact factor: 4.129
Authors: Miguel A Carbajo; Enrique Luque-de-León; José M Jiménez; Javier Ortiz-de-Solórzano; Manuel Pérez-Miranda; María J Castro-Alija Journal: Obes Surg Date: 2017-05 Impact factor: 4.129
Authors: Mario Musella; Mervyn Deitel; K S Kular; Miguel-A Carbajo; Karl P Rheinwalt; Chetan Parmar; Arun Prasad; Enrique Luque-de-Leon; Gurvinder Jammu; Roger Luciani; David Hargroder; Cesare Pereaglie; Jean Marc Chevallier Journal: Obes Surg Date: 2019-02 Impact factor: 4.129
Authors: Conor Brosnan; Jarlath C Bolger; Eamonn M Bolger; Michael E Kelly; Roisin Tully; Mohamed AlAzzawi; William B Robb Journal: Obes Surg Date: 2020-08-21 Impact factor: 4.129
Authors: Jaime Ruiz-Tovar; Miguel A Carbajo; Jose M Jimenez; Enrique Luque-de-Leon; Javier Ortiz-de-Solorzano; Maria J Castro Journal: World J Surg Date: 2020-03 Impact factor: 3.352